BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Stock analysts at Diamond Equity issued their Q1 2026 EPS estimates for shares of BioHarvest Sciences in a research note issued to investors on Thursday, April 3rd. Diamond Equity analyst H. Diamond anticipates that the company will earn ($0.01) per share for the quarter. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. Diamond Equity also issued estimates for BioHarvest Sciences' Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.03 EPS and Q4 2026 earnings at $0.06 EPS.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.05). The business had revenue of $7.17 million for the quarter, compared to analyst estimates of $7.24 million.
Several other equities analysts have also issued reports on BHST. Maxim Group assumed coverage on BioHarvest Sciences in a research note on Wednesday, December 18th. They issued a "buy" rating and a $12.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $14.00 price objective on shares of BioHarvest Sciences in a research note on Tuesday.
Check Out Our Latest Report on BHST
BioHarvest Sciences Price Performance
Shares of BioHarvest Sciences stock traded up $0.06 on Monday, hitting $5.61. 28,642 shares of the company's stock traded hands, compared to its average volume of 10,802. The firm's fifty day moving average price is $5.73. BioHarvest Sciences has a one year low of $5.40 and a one year high of $7.38. The company has a market cap of $92.14 million, a P/E ratio of -4.49 and a beta of 0.84.
Institutional Trading of BioHarvest Sciences
A hedge fund recently raised its stake in BioHarvest Sciences stock. Magnus Financial Group LLC boosted its position in BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) by 105.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 71,733 shares of the company's stock after acquiring an additional 36,733 shares during the period. Magnus Financial Group LLC owned 0.44% of BioHarvest Sciences worth $444,000 as of its most recent SEC filing.
BioHarvest Sciences Company Profile
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Further Reading
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
